105
Participants
Start Date
September 6, 2012
Primary Completion Date
January 23, 2014
Study Completion Date
January 23, 2014
Previous treatment in DEB025 study
Follow-up after DEB025 active study
Novartis Investigative Site, Douliu
Novartis Investigative Site, Budapest
Novartis Investigative Site, Westmead
Novartis Investigative Site, Leuven
Novartis Investigative Site, Torino
Novartis Investigative Site, Berlin
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Kiel
Novartis Investigative Site, Pavia
Novartis Investigative Site, Hanover
Novartis Investigative Site, Linkou District
Novartis Investigative Site, Taichung
Novartis Investigative Site, Parma
Novartis Investigative Site, Busan
Novartis Investigative Site, Cologne
Novartis Investigative Site, Springfield
Novartis Investigative Site, Arlington
Novartis Investigative Site, Houston
Novartis Investigative Site, San Antonio
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Kaohsiung City
Novartis Investigative Site, Songkhla
Novartis Investigative Site, San Diego
Novartis Investigative Site, Ventura
Novartis Investigative Site, Honolulu
Novartis Investigative Site, Iași
Novartis Investigative Site, Torono
Novartis Investigative Site, Mumbai
Novartis Investigative Site, Roma
Novartis Investigative Site, Bialystok
Novartis Investigative Site, Warsaw
Novartis Investigative Site, San Juan
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Bucharest
Novartis Investigative Site, Pusan
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Ho Chi Minh City
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY